Clinical Trial Update: Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AZD2014 in combination with palbociclib for estrogen receptor-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Metastatic Breast Cancer

Drugs mentioned

• AZD2014 (vistusertib)
• Palbociclib (Ibrance) (palbociclib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced and Metastatic Breast Cancer | Phase 1 | Status: COMPLETED